Broadcast Date: Tuesday, November 12, 2024
Time: 8:00 am PT, 11:00 am ET, 17:00 CET
For adeno-associated viral gene therapies to scale, scientists must first address safety and manufacturability challenges. Improving payload design and optimizing production systems can help scientists address those challenges and ensure the safety, efficacy, and scalability of their therapies.
In this GEN webinar, Mark Stockdale will discuss how the application of synthetic biology and artificial intelligence can be used to improve the safety, potency and manufacturability of gene therapies, and introduce AAV Edge, a comprehensive platform for end-to-end gene therapy optimization—from payload design to production cell lines and model-guided processes.
Key topics that will be covered in the webinar include:
- How an in-house transformer-based model is used to design tissue-specific promoters, resulting in a >200-fold dynamic range in expression between on-target vs. off-target tissues.
- How sequence optimization boosts expression for clinically relevant transgenes up to 7-fold.
- How silencing of transgene expression in the production cell line can reduce cellular stress and toxicity during the manufacturing process.
- How the combination of Asimov’s clonal HEK293 cell line, optimized two-plasmid system, and model-driven process development achieves unconcentrated titers of up to 1E12 viral genomes per milliliter (vg/mL) across multiple serotypes.
Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Preclinical Studies Highlight Novel Gene Therapy for IgA Nephropathy Treatment
San Diego, CA – October 28, 2024 At the recent ASN Kidney Week 2024 (October 23–27), researchers presented promising preclinical data on PS-002, an innovative gene therapy aimed at treating IgA nephropathy (IgAN), an autoimmune kidney disease. The therapy, developed...
[2024/10/25] Gene and Cell Therapy- weekly digest from PackGene
FeaturedNewsArticlesPackGene's NewsletterReceive the latest news and insights to your inbox.About PackGenePackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span...
Lipin1 Inhibition Enhances Axon Regeneration: A Potential Therapeutic Approach for Spinal Cord Injury
Traumatic injuries to the central nervous system (CNS) often result in permanent functional deficits due to the limited capacity of CNS neurons to regenerate. Although advancements in spinal cord injury (SCI) research have been made, achieving substantial nerve fiber...
CRISPR therapy reduces swelling attacks by 81% in Intellia follow-up study
The promise of a one-and-done CRISPR infusion is beginning to look more real than ever. On Thursday, Intellia Therapeutics announced that an experimental gene editing therapy reduced dangerous and unpredictable swelling attacks caused by the disease hereditary...
Related Services
AAV Packaging Services
READ MORE
Off-the-Shelf AAV Products
READ MORE
